Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Konovalov, Sergiy ^a   Garcia Bassets, Ivan ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell cycle; Human ovarian tumors; Immune response; Inflammatory response; LSD1 inhibitors; LSD1 KDM1A AOF2; RT qPCR; Subtype C5; TCGA; Transcriptomic signature

Indexed keywords

ANTINEOPLASTIC AGENT; CAS 927019; CBB 1007; CISPLATIN; LYSINE SPECIFIC DEMETHYLASE 1; MEMBRANE PROTEIN; MESSENGER RNA; PARGYLINE; RN 1; S 2101; TRANS 2 PHENYLCYCLOPROPYL AMINE HYDROCHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER STAGING; CELL ASSAY; CELL CYCLE; CELL VIABILITY; COHORT ANALYSIS; CYSTADENOCARCINOMA; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; UPREGULATION; WESTERN BLOTTING;

EID: 84886410044     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-75     Document Type: Article

References (58)

1. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y, Cell 2004 119 941 953 (Pubitemid 40037608)
2. LSD1 and the chemistry of histone demethylation. Culhane JC, Cole PA, Curr Opin Chem Biol 2007 11 561 568 (Pubitemid 47588999)
3. LSD1 demethylates histone and non-histone proteins. Nicholson TB, Chen T, Epigenetics 2009 4 129 132
4. New roles of flavoproteins in molecular cell biology: histone demethylase LSD1 and chromatin. Forneris F, Battaglioli E, Mattevi A, Binda C, FEBS J 2009 276 4304 4312
5. Regulation of LSD1 histone demethylase activity by its associated factors. Shi Y-J, Matson C, Lan F, Iwase S, Baba T, Shi Y, Mol Cell 2005 19 857 864 (Pubitemid 41316679)
6. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Müller JM, Greschik H, Kirfel J, Ji S, Kunowska N, Beisenherz-Huss C, Günther T, Buettner R, Schüle R, Nature 2010 464 792 796
7. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AHFM, Günther T, Buettner R, Schüle R, Nature 2005 437 436 439 (Pubitemid 41613508)
8. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Garcia-Bassets I, Kwon Y-S, Telese F, Prefontaine GG, Hutt KR, Cheng CS, Ju B-G, Ohgi KA, Wang J, Escoubet-Lozach L, Rose DW, Glass CK, Fu X-D, Rosenfeld MG, Cell 2007 128 505 518 (Pubitemid 46198894)
9. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schüle R, Brann DW, Tekmal RR, Vadlamudi RK, EMBO Rep 2010 11 438 444
10. LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV, Majello B, Oncogene 2010 29 3691 3702
11. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. Lin Y, Wu Y, Li J, Dong C, Ye X, Chi Y-I, Evers BM, Zhou BP, EMBO J 2010 29 1803 1816
12. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Lin T, Ponn A, Hu X, Law BK, Lu J, Oncogene 2010 29 4896 4904
13. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP, Nat Struct Mol Biol 2011 18 867 874
14. p53 is regulated by the lysine demethylase LSD1. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL, Nature 2007 449 105 108 (Pubitemid 47373772)
15. Lysine methylation regulates E2F1-induced cell death. Kontaki H, Talianidis I, Mol Cell 2010 39 152 160
16. Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. Zhao Z-K, Yu H-F, Wang D-R, Dong P, Chen L, Wu W-G, Ding W-J, Liu Y-B, World J Gastroenterol 2012 18 6651 6656
17. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch LK, Höller T, Büttner R, Lüscher B, Gütgemann I, Hum Pathol 2010 41 181 189
18. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J, Carcinogenesis 2010 31 512 520
19. Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R, BMC Clin Pathol 2012 12 13
20. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Hayami S, Kelly JD, Cho H-S, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BAJ, Nakamura Y, Hamamoto R, Int J Cancer 2011 128 574 586
21. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H, Hum Pathol 2012 43 1300 1307
22. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J, Cancer Res 2009 69 2065 2071
23. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R, Cancer Res 2006 66 11341 11347 (Pubitemid 46009965)
24. Inhibitors of histone demethylases. Lohse B, Kristensen JL, Kristensen LH, Agger K, Helin K, Gajhede M, Clausen RP, Bioorg Med Chem 2011 19 3625 3636
25. Lysine demethylases inhibitors. Suzuki T, Miyata N, J Med Chem 2011 54 8236 8250
26. Polyamine analogues targeting epigenetic gene regulation. Huang Y, Marton LJ, Woster PM, Casero RA, Essays Biochem 2009 46 95 110
27. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr, Proc Natl Acad Sci U S A 2007 104 8023 8028 (Pubitemid 47185869)
28. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B, Jones RJ, Woster PM, Casero RA Jr, Clin Cancer Res 2009 15 7217 7228
29. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr, Amino Acids 2012 42 887 898
30. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R, Chem Biol 2006 13 563 567
31. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Schmidt DMZ, McCafferty DG, Biochemistry 2007 46 4408 4416 (Pubitemid 46559406)
32. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Yang M, Culhane JC, Szewczuk LM, Jalili P, Ball HL, Machius M, Cole PA, Yu H, Biochemistry 2007 46 8058 8065 (Pubitemid 47051641)
33. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S, Biochemistry 2010 49 6494 6503
34. Brain-penetrant LSD1 inhibitors can block memory consolidation. Neelamegam R, Ricq EL, Malvaez M, Patnaik D, Norton S, Carlin SM, Hill IT, Wood MA, Haggarty SJ, Hooker JM, ACS Chem Neurosci 2012 3 120 128
35. Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase. Tortorici M, Borrello MT, Tardugno M, Chiarelli LR, Pilotto S, Ciossani G, Vellore NA, Bailey SG, Cowan J, O'Connell M, Crabb SJ, Packham G, Mai A, Baron R, Ganesan A, Mattevi A, ACS Chem Biol 2013 8 1677 1682
36. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, Liu Y, Ward D, Quan J, Ye T, Zhang H, Cancer Res 2011 71 7238 7249
37. The UCSC Cancer Genomics Browser: update 2013. Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D, Zhu J, Nucleic Acids Res 2013 41 Database issue 949 D954
38. Open source clustering software. De Hoon MJL, Imoto S, Nolan J, Miyano S, Bioinformatics 2004 20 1453 1454 (Pubitemid 38931415)
39. Ovarian cancer. Cho KR, Shih I-M, Annu Rev Pathol 2009 4 287 313
40. Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms. Jones PM, Drapkin R, Front Oncol 2013 3 217
41. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew Y-E, Haviv I, Gertig D, DeFazio A, Bowtell DDL, Clin Cancer Res 2008 14 5198 5208
42. The new face of ovarian cancer modeling: better prospects for detection and treatment. Karst AM, Drapkin R, F1000 Med Rep 2011 3 22
43. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Maines-Bandiera SL, Kruk PA, Auersperg N, Am J Obstet Gynecol 1992 167 729 735
44. Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Berthon P, Waller AS, Villette JM, Loridon L, Cussenot O, Maitland NJ, Int J Cancer 1997 73 910 916 (Pubitemid 127483050)
45. Short-term primary culture of epithelial cells derived from human breast tumours. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB, Atkin SL, Br J Cancer 1998 78 1421 1429 (Pubitemid 28517537)
46. Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer. O'Shannessy DJ, Jackson SM, Twine NC, Hoffman BE, Dezso Z, Agoulnik SI, Somers EB, Int J Mol Sci 2013 14 13687 13703
47. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, Zhu P, Garcia-Bassets I, Liu F, Taylor H, Lozach J, Jayes FL, Korach KS, Glass CK, Fu X-D, Rosenfeld MG, Nature 2007 446 882 887 (Pubitemid 46633160)
48. Lysine-specific histone demethylase 1 (LSD1): a potential molecular target for tumor therapy. Chen Y, Jie W, Yan W, Zhou K, Xiao Y, Crit Rev Eukaryot Gene Expr 2012 22 53 59
49. T-regulatory cells: key players in tumor immune escape and angiogenesis. Facciabene A, Motz GT, Coukos G, Cancer Res 2012 72 2162 2171
50. Deciphering and reversing tumor immune suppression. Motz GT, Coukos G, Immunity 2013 39 61 73
51. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N, Cancer Discovery 2012 2 401 404
52. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Shi L, Cui S, Engel JD, Tanabe O, Nat Med 2013 19 291 294
53. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein H-U, Popescu AC, Burnett A, Mills K, Casero RA Jr, Marton L, Woster P, Minden MD, Dugas M, Wang JCY, Dick JE, Müller-Tidow C, Petrie K, Zelent A, Nat Med 2012 18 605 611
54. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, Cowley SM, Young RA, Nature 2012 482 221 225
55. FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure. Hino S, Sakamoto A, Nagaoka K, Anan K, Wang Y, Mimasu S, Umehara T, Yokoyama S, Kosai K-I, Nakao M, Nat Commun 2012 3 758
56. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T, Nature 2000 406 593 599 (Pubitemid 30641039)
57. Targeting protein lysine methylation and demethylation in cancers. He Y, Korboukh I, Jin J, Huang J, Acta Biochim Biophys Sin (Shanghai) 2012 44 70 79
58. A general molecular affinity strategy for global detection and proteomic analysis of lysine methylation. Moore KE, Carlson SM, Camp ND, Cheung P, James RG, Chua KF, Wolf-Yadlin A, Gozani O, Mol Cell 2013 50 444 456